Chordoma: The entity

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 655-669

  Yakkioui, Youssef ^a   van Overbeeke, Jacobus J ^a   Santegoeds, Remco ^a   van Engeland, Manon ^a   Temel, Yasin ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chordoma; Epigenetics; Etiology; Notochord; Pathophysiology; Tumor biology

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GALECTIN 3; IMATINIB; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN PATCHED 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; STEM CELL FACTOR RECEPTOR; UVOMORULIN; WNT1 PROTEIN; CADHERIN;

CELL CYCLE REGULATION; CHORDOMA; CHROMOSOME ABERRATION; DISEASE COURSE; EMBRYOLOGY; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; NOTOCHORD; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SECOND CERVICAL VERTEBRA; SKULL BASE; CELL CYCLE; DNA METHYLATION; GENETICS; PATHOLOGY; PHYSIOLOGY;

CADHERINS; CELL CYCLE; CHORDOMA; DNA METHYLATION; HUMANS; NOTOCHORD; RECEPTOR PROTEIN-TYROSINE KINASES; SKULL BASE;

EID: 84911373557     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.07.012     Document Type: Review

References (232)

1. Smoll N.R., Gautschi O.P., Radovanovic I., Schaller K., Weber D.C. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer 2013, 119:2029-2037.
2. Casali P.G., Stacchiotti S., Sangalli C., Olmi P., Gronchi A. Chordoma. Curr Opin Oncol 2007, 19:367-370.
3. Amichetti M., Cianchetti M., Amelio D., Enrici R.M., Minniti G. Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg. Rev. 2009, 32:403-416.
4. Staab A., et al. Spot-scanning-based proton therapy for extracranial chordoma. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81(4):e489-e496.
5. Dorfman H.D., Czerniak B. Bone cancers. Cancer 1995, 75:203-210.
6. McMaster M.L., Goldstein A.M., Bromley C.M., Ishibe N., Parry D.M. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001, 12:1-11.
7. Mukherjee D., et al. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J. Neurosurg. Spine 2011, 14:143-150.
8. Jacob H.E. Chemotherapy for cranial base tumors. J. Neuro-Oncol. 1994, 20:327-335.
9. Luschka H. Die Altersveränderungen der Zwischenwirbelknorpel. Virchows Arch.Pathol Anat Histol. 1856, 9:311-327.
10. Muller H. Uber das Vorkommen von Resten der Chorda dorsalis bei Menschen nach der Geburt und uber ihr Verhaltnis zu den Gallert-geschwulsten am Clivus. Ztschr f. rat. Med 1858, 2:202-230.
11. Kyriakos M., Totty W.G., Lenke L.G. Giant vertebral notochordal rest: a lesion distinct from chordoma: discussion of an evolving concept. Am. J. Surg. Pathol. 2003, 27:396-406.
12. Schoenwolf G.C., Larsen W.J. Third week: becomming trilaminar and establishing body axis. Larsen's Human Embryology 2009, /Elsevier/Churchill Livingstone, Philadelphia.
13. Bumcrot D.A., McMahon A.P. Somite differentiation. Curr.Biol. 1995, 5:612-614.
14. Liem K.F., Jessell T.M., Briscoe J. Regulation of the neural patterning activity of sonic hedgehog by secreted BMP inhibitors expressed by notochord and somites. Development 2000, 127:4855-4866.
15. Stemple D.L. Structure and function of the notochord: an essential organ for chordate development. Development 2005, 132:2503-2512.
16. Salisbury J.R., Isaacson P.G. Demonstration of cytokeratins and an epithelial membrane antigen in chordomas and human fetal notochord. Am. J. Surg. Pathol. 1985, 9:791-797.
17. Pourquie O., Coltey M., Teillet M.A., Ordahl C., Le Douarin N.M. Control of dorsoventral patterning of somitic derivatives by notochord and floor plate. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5242-5246.
18. Claudio D.S. Grafting of somites. Methods Mol. Biol. 2008, 461:277-287.
19. Dietrich S., Schubert F.R., Gruss P. Altered Pax gene expression in murine notochord mutants: the notochord is required to initiate and maintain ventral identity in the somite. Mech. Dev. 1993, 44:189-207.
20. Alvares L.E., Lours C., El-Hanfy A., Dietrich S. Microsurgical manipulation of the notochord. Methods Mol. Biol. 2008, 461:289-303.
21. Resende T.P., et al. Sonic hedgehog in temporal control of somite formation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:12907-12912.
22. Fleming A., Keynes R.J., Tannahill D. The role of the notochord in vertebral column formation. J. Anat. 2001, 199:177-180.
23. Moore K.L., Persaud T.V.N., Torchia M.G. The Developing Human: Clinically Oriented Embryology 2008, Saunders/Elsevier, Philadelphia, PA.
24. Bogduk N. Embryology and development. Clinical Anatomy of the Lumbar Spine and Sacrum 2005, 149-163. Elsevier/Churchill Livingstone, Edinburgh.
25. Christ B., Huang R., Scaal M. Formation and differentiation of the avian sclerotome. Anat. Embryol. 2004, 208:333-350.
26. Rodrigo I., Hill R.E., Balling R., Munsterberg A., Imai K. Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome. Development 2003, 130:473-482.
27. Oka Y., et al. Epimorphin acts extracellularly to promote cell sorting and aggregation during the condensation of vertebral cartilage. Dev. Biol. 2006, 291:25-37.
28. Kim K.W., et al. The origin of chondrocytes in the nucleus pulposus and histologic findings associated with the transition of a notochordal nucleus pulposus to a fibrocartilaginous nucleus pulposus in intact rabbit intervertebral discs. Spine 2003, 28:982-990. (Phila Pa 1976).
29. Aszodi A., Chan D., Hunziker E., Bateman J.F., Fassler R. Collagen II is essential for the removal of the notochord and the formation of intervertebral discs. J. Cell Biol. 1998, 143:1399-1412.
30. Gilbert S.F. Developmental Biology 2010, Sinauer Associates, Sunderland.
31. Guehring T., Nerlich A., Kroeber M., Richter W., Omlor G.W. Sensitivity of notochordal disc cells to mechanical loading: an experimental animal study. Eur. Spine J. 2010, 19:113-121.
32. Hunter C.J., Matyas J.R., Duncan N.A. The notochordal cell in the nucleus pulposus: a review in the context of tissue engineering. Tissue Eng. 2003, 9:667-677.
33. Horwitz T. The Human Notochord: A Study of Its Development and Regression, Variations, and Pathologic Derivative, Chordoma 1977.
34. Peacock A. Observations on the postnatal structure of the intervertebral disc in man. J. Anat. 1952, 86:162-179.
35. Nishiguchi T., Mochizuki K., Tsujio T., Nishita T., Inoue Y. Lumbar vertebral chordoma arising from an intraosseous benign notochordal cell tumour: radiological findings and histopathological description with a good clinical outcome. Br. J. Radiol. 2010, 83:e49-e53.
36. Yamaguchi T., Suzuki S., Ishiiwa H., Ueda Y. Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas?. Histopathology 2004, 44:597-602.
37. Yamaguchi T., Yamato M., Saotome K. First histologically confirmed case of a classic chordoma arising in a precursor benign notochordal lesion: differential diagnosis of benign and malignant notochordal lesions. Skelet. Radiol. 2002, 31:413-418.
38. Amer H.Z., Hameed M. Intraosseous benign notochordal cell tumor. Arch. Pathol. Lab. Med. 2010, 134:283-288.
39. Shen J., et al. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. J. Clin. Neurosci. 2011, 18:96-99.
40. Belden C.J. The skull base and calvaria. Neuroimaging Clin. N. Am. 1998, 8:1-20.
41. Scheuer L., Black S.M. Developmental Juvenile Osteology 2000, 36-171. Academic Press, San Diego, Calif.; London.
42. Young B., et al. Indian and sonic hedgehogs regulate synchondrosis growth plate and cranial base development and function. Dev. Biol. 2006, 299:272-282.
43. Stewart M.J., Burrow J.L.F. Ecchordosis physaliphora Spheno-occipitalis. J. Neurol. Psychopathol. 1923, 1-4:218-220.
44. Wyatt R.B., Schochet S.S., McCormick W.F. Ecchordosis physaliphora. An electron microscopic study. J. Neurosurg. 1971, 34:672-677.
45. Luschka H. Ueber gallertartige Auswüchse am Clivus Blumenbachii. Archiv f. pathol. Anat. 1857, 11:8-12.
46. Virchow R. Untersuchungen uber die Entwickelung des Schadelgrundes im gesunden und krankhaften Zustande, und uber den Einfluss derselben auf Schadelform, Gesichtsbildung und Gehirnbau. G. Rimer,Berl. 1857, 47.
47. Ribbert H. Uber die Eccondrosis physaliphora spheno-occipitalis. Zertralbl. f. allg. Path. u. Path.Anat. 1894, 5457.
48. Ribbert H. Uber die experimentalle Erzeugung einer Eccondrosis physaliphora. Verhandl. d. Kong. f. Inh. Med 1895, 13:455.
49. Horwitz T. Chordal ectopia and its possible relation to chordoma. Arch. Pathol. 1941, 31:354-356.
50. Mehnert F., Beschorner R., Kuker W., Hahn U., Nagele T. Retroclival ecchordosis physaliphora: MR imaging and review of the literature. AJNR Am. J. Neuroradiol. 2004, 25:1851-1855.
51. Krisht K.M., Palmer C.A., Osborn A.G., Couldwell W.T. Giant ecchordosis physaliphora in an adolescent girl. J. Neurosurg. Pediatr. 2013, 12:328-333.
52. Ciarpaglini R., et al. Intradural clival chordoma and ecchordosis physaliphora: a challenging differential diagnosis: case report. Neurosurgery 2009, 64:E387-E388. (discussion E388).
53. Macdonald R.L., Deck J.H. Immunohistochemistry of ecchordosis physaliphora and chordoma. J. neurol. sci. 1990, 17:420-423.
54. Rosenberg A.E., Brown G.A., Bhan A.K., Lee J.M. Chondroid chordoma-a variant of chordoma. Am. J.Clin. Pathol. 1994, 101:36-41.
55. Gibbs C.P., et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005, 7:967-976.
56. Schatton T., Frank M.H. The in vitro spheroid melanoma cell culture assay: cues on tumor initiation [quest]. J Invest. Dermatol. 2010, 130:1769-1771.
57. Hsu W., et al. Identification of cancer stem cells in human chordoma. 27th Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves J. Neurosurg. Neurosurg. Focus 2011, 30(3):A1-A25.
58. Vujovic S., et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J. Pathol. 2006, 209:157-165.
59. Sangoi A.R., et al. Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases. Mod. Pathol. 2011, 24:425-429.
60. Oakley G.J., Fuhrer K., Seethala R.R. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod. Pathol. 2008, 21:1461-1469.
61. Palena C., et al. The human T-box mesodermal transcription factor brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin. Cancer Res. 2007, 13:2471-2478.
62. Hayashi T., et al. Cytopathologic features of orbital intraosseous chordoid meningioma: report of a case and distinction from other myxoid/mucoid tumors. Diagn. Cytopathol. 2010, 38:818-821.
63. O'Donnell P., et al. Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skelet. Radiol. 2007, 36:59-65.
64. Shen J., et al. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. J. Clin. Neurosci. 2010, 18(1):96-99.
65. Tirabosco R., et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am. J. Surg. Pathol. 2008, 32:572-580.
66. Presneau N., et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J. Pathol. 2011, 223:327-335.
67. Hsu W., et al. Generation of chordoma cell line, JHC7, and the identification of brachyury as a novel molecular target. J. Neurosurg. Neurosurg. Focus. 2011, 30(3):A1-A25.
68. Shalaby A.A., et al. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod. Pathol. 2009, 22:996-1005.
69. Gotz W., Kasper M., Miosge N., Hughes R.C. Detection and distribution of the carbohydrate binding protein galectin-3 in human notochord, intervertebral disc and chordoma. Res. Biol.Divers. 1997, 62:149-157.
70. ENDO K., et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005, 25:3117-3121.
71. Buljan M., Šitum M., Tomas D., Milošević M., Krušlin B. Prognostic value of galectin-3 in primary cutaneous melanoma. J. Eur. Acad. Dermatol. Venereol. 2011, 25:1174-1181.
72. Ukita K., et al. Wnt signaling maintains the notochord fate for progenitor cells and supports the posterior extension of the notochord. Mech. Dev. 2009, 126:791-803.
73. Morin P.J. β-Catenin signaling and cancer. BioEssays 1999, 21:1021-1030.
74. Nagayama M., et al. Wnt/beta-catenin signaling regulates cranial base development and growth. J. Dent. Res. 2008, 87:244-249.
75. Yamaguchi T.P., Takada S., Yoshikawa Y., Wu N., McMahon A.P. T (brachyury) is a direct target of Wnt3a during paraxial mesoderm specification. Genes Dev. 1999, 13:3185-3190.
76. Vonica A., Gumbiner B.M. Zygotic Wnt activity is required for brachyury expression in the early Xenopus laevis embryo. Dev. Biol. 2002, 250:112-127.
77. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8:387-398.
78. Mosimann C., Hausmann G., Basler K. β-Catenin hits chromatin: regulation of Wnt target gene activation. Nat. Rev. Mol. Cell Biol. 2009, 10:276-286.
79. Cho H.Y., et al. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. Appl. Immunohistochem. Mol. Morphol. 2009, 17:131-138.
80. Horiguchi H., et al. Expression of cell adhesion molecules in chordomas: an immunohistochemical study of 16 cases. Acta Neuropathol. 2004, 107:91-96.
81. Triana A., Sen C., Wolfe D., Hazan R. Cadherins and catenins in clival chordomas: correlation of expression with tumor aggressiveness. Am. J. Surg. Pathol. 2005, 29:1422-1434.
82. Hendriksen J., et al. Plasma membrane recruitment of dephosphorylated beta-catenin upon activation of the Wnt pathway. J. Cell Sci. 2008, 121:1793-1802.
83. Wahl J.K., Kim Y.J., Cullen J.M., Johnson K.R., Wheelock M.J. N-cadherin-catenin complexes form prior to cleavage of the proregion and transport to the plasma membrane. J. Biol. Chem. 2003, 278:17269-17276.
84. Riva P., et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int. J. Cancer 2003, 107:493-497.
85. Weed M., Mundlos S., Olsen B.R. The role of sonic hedgehog in vertebrate development. Matrix Biol. 1997, 16:53-58.
86. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9:873-886.
87. Brandner S. Nanog, Gli, and p53: a new network of stemness in development and cancer. EMBO J. 2010, 29:2475-2476.
88. Cates J.M., Itani D.M., Coffin C.M., Harfe B.D. The sonic hedgehog pathway in chordoid tumours. Histopathology 2010, 56:978-979.
89. Miozzo M., et al. A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int. J. Cancer 2000, 87:68-72.
90. Kelley M.J., et al. Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33. Am. J. Hum. Genet. 2001, 69:454-460.
91. Larizza L., Mortini P., Riva P. Update on the cytogenetics and molecular genetics of chordoma. Hered. Cancer. Clin. Pract. 2005, 3:29-41.
92. Yang X.R., et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat. Genet. 2009, 41:1176-1178.
93. Almefty K.K., Pravdenkova S., Sawyer J., Al-Mefty O. Impact of cytogenetic abnormalities on the management of skull base chordomas. J. Neurosurg. 2009, 110:715-724.
94. Gil Z., et al. Cytogenetic analysis of three variants of clival chordoma. Cancer Genet. Cytogenet. 2004, 154:124-130.
95. Hruban R.H., Traganos F., Reuter V.E., Huvos A.G. Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am. J. Pathol. 1990, 137:435-447.
96. Kuzniacka A., Mertens F., Strombeck B., Wiegant J., Mandahl N. Combined binary ratio labeling fluorescence in situ hybridization analysis of chordoma. Cancer Genet. Cytogenet. 2004, 151:178-181.
97. Scheil S., et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosom. Cancer 2001, 32:203-211.
98. Mitchell A., et al. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 1993, 72:2943-2949.
99. Sawyer J.R., Husain M., Al-Mefty O. Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: a new marker for aggressive tumors?. Neurosurg. Focus. 2001, 10:E6.
100. Colli B.O., Al-Mefty O. Chordomas of the skull base: follow-up review and prognostic factors. Neurosurg. Focus. 2001, 10:E1.
101. Bayrakli F., Guney I., Kilic T., Ozek M., Pamir M.N. New candidate chromosomal regions for chordoma development. Surg. Neurol. 2007, 68:425-430. (discussion 430).
102. Brandal P., Bjerkehagen B., Danielsen H., Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet. Cytogenet. 2005, 160:15-21.
103. Tallini G., et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J. Pathol. 2002, 196:194-203.
104. Schoedel K.E., Martinez A.J., Mahoney T.M., Contis L., Becich M.J. Chordomas: pathological features; ploidy and silver nucleolar organizing region analysis. A study of 36 cases. Acta Neuropathol. 1995, 89:139-143.
105. Thompson S.L., Bakhoum S.F., Compton D.A. Mechanisms of chromosomal instability. Curr. Biol. 2010, 20:R285-R295.
106. Zhou X.Z., et al. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J. Clin. Invest. 2011, 121(4).
107. Greenberg R.A. Telomeres, crisis and cancer. Curr. Mol. Med. 2005, 5:213-218.
108. Gisselsson D., et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc. Natl. Acad. Sci. 2001, 98:12683-12688.
109. Cui W., et al. Stabilization of telomere length and karyotypic stability are directly correlated with the level of hTERT gene expression in primary fibroblasts. J. Biol. Chem. 2002, 277:38531-38539.
110. Albanell J., et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J. Natl. Cancer Inst. 1997, 89:1609-1615.
111. Papadopoulou A., et al. Telomerase activity and genetic alterations in primary breast carcinomas. Neoplasia 2003, 5:170-178.
112. Izumi H., et al. High telomerase activity correlates with the stabilities of genome and DNA ploidy in renal cell carcinoma. Neoplasia 2002, 4:103-111.
113. Aue G., Muralidhar B., Schwartz H.S., Butler M.G. Telomerase activity in skeletal sarcomas. Ann. Surg. Oncol. 1998, 5:627-634.
114. Butler M.G., et al. Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas. Cancer Genet. Cytogenet. 1995, 85:51-57.
115. Butler M.G., Sciadini M., Hedges L.K., Schwartz H.S. Chromosome telomere integrity of human solid neoplasms. Cancer Genet. Cytogenet. 1996, 86:50-53.
116. Pallini R., et al. Chordoma of the skull base: predictors of tumor recurrence. J. Neurosurg. 2003, 98:812-822.
117. Ricci-Vitiani L., et al. Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. J. Neurosurg. 2006, 105:482-484.
118. Stephens P.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
119. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
120. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
121. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. N. Y. Acad. Sci. 2000, 910:121-137. (discussion 137-139).
122. Naka T., et al. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer 2005, 104:1255-1263.
123. Horbinski C., et al. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch. Pathol. Lab. Med. 2010, 134:1170-1176.
124. Kilgore S., Prayson R.A. Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann. Diagn. Pathol. 2002, 6:222-228.
125. Matsuno A., et al. Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas. Hum. Pathol. 1997, 28:714-719.
126. Naka T., et al. Proliferative activities in conventional chordoma: a clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special reference to anaplastic chordoma showing a diffuse proliferation and nuclear atypia. Hum. Pathol. 1996, 27:381-388.
127. Bergh P., et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000, 88:2122-2134.
128. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry?. J. Pathol. 1992, 166:329-330.
129. Manfredi J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010, 24:1580-1589.
130. Cordon-Cardo C., et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994, 54:794-799.
131. Sasaki M., Nie L., Maki C.G. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J. Biol. Chem. 2007, 282:14626-14634.
132. Qiu W., et al. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells. Oncogene 2008, 27:4034-4043.
133. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
134. Ragland B.D., Bell W.C., Lopez R.R., Siegal G.P. Cytogenetics and molecular biology of osteosarcoma. Lab. Invest. 2002, 82:365-373.
135. Liu H., Dibling B., Spike B., Dirlam A., Macleod K. New roles for the RB tumor suppressor protein. Genet. Dev. 2004, 14:55-64.
136. Myong N.H. Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res. Treat. 2008, 40:45-52.
137. Eisenberg MB W.M., Sen C., Wolfe D. Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg. Neurol. 1997, 47:156-160.
138. Romagosa C., et al. p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011, 30:2087-2097.
139. Hallor K.H., et al. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br. J. Cancer 2008, 98:434-442.
140. Sommer J., et al. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J. Pathol. 2010, 220:608-617.
141. Presneau N., et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br. J. Cancer 2009, 100:1406-1414.
142. Thoms H.C., Dunlop M.G., Stark L.A. CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA. Cell Cycle 2007, 6:1293-1297.
143. Alberts B. Mechanism of cell communication. Molecular Biology of the Cell 2008, 879-964. Garland Science, New York.
144. Bennasroune A., Gardin A., Aunis D., Crémel G., Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol./Hematol. 2004, 50:23-38.
145. Fasig J.H., Dupont W.D., LaFleur B.J., Olson S.J., Cates J.M. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol. Appl. Neurobiol. 2008, 34:95-104.
146. Orzan F., et al. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol. Rep. 2007, 18:249-252.
147. Stacchiotti S., et al. Imatinib mesylate in advanced chordoma: a multicenter phase II study. J. Clin. Oncol. 2007, 25.
148. Tamborini E., et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin. Cancer Res. 2006, 12:6920-6928.
149. Tamborini E., et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro. Oncol. 2010, 12:776-789.
150. Walter B.A., et al. Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression. J. Neuro.oncol. 2011, 101(2):199-206.
151. Weinberger P.M., et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch. Otolaryngol. Head Neck Surg. 2005, 131:707-711.
152. Ostroumov E., Hunter C.J. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein. Spine 2008, 33:2774-2780. (Phila Pa 1976).
153. Caron E., et al. A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 2010, 6.
154. Shalaby A., et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J. Pathol. 2011, 223(3):336-346.
155. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
156. Wan P.T.C., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
157. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
158. SCHWAB J. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009, 29:1867-1871.
159. Kuemmerle J.F. Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3β activity. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G101-G110.
160. Cheong J.W., et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br. J. Haematol. 2003, 122:454-456.
161. Bilanges B., Vanhaesebroeck B. A new tool to dissect the function of p70 S6 kinase. Biochem. J. 2010, 431:e1-e3.
162. Montagne J., et al. Drosophila S6 kinase: a regulator of cell size. Science 1999, 285:2126-2129.
163. Han S., et al. Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin. Cancer Res. 2009, 15:1940-1946.
164. Zhou J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. 2007, 104:16158-16163.
165. Yang C., et al. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol. Cancer Ther. 2009, 8:2597-2605.
166. Yang C., et al. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine 2010, 35:1668-1675. (Phila Pa 1976).
167. Hsieh A.C., Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin. Cancer Res. 2010, 16:4914-4920.
168. Lu Y., et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 2003, 278:40057-40066.
169. Li A.G., et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell 2006, 23:575-587.
170. Freeman D.J., et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003, 3:117-130.
171. Chan J.A., et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropathol. Exp. Neurol. 2004, 63:1236-1242.
172. Kimmell K.T., Dayoub H., Stolzenberg E.D., Sincoff E.H. Chordoma in the lateral medullary cistern in a patient with tuberous sclerosis: a case report and review of the literature. Surg. Neurol. Int. 2010, 1:13.
173. Borgel J., Olschewski H., Reuter T., Miterski B., Epplen J.T. Does the tuberous sclerosis complex include clivus chordoma? A case report. Eur. J. Pediatr. 2001, 160:138.
174. Dutton R.V., Singleton E.B. Tuberous sclerosis: a case report with aortic aneurysm and unusual rib changes. Pediatr. Radiol. 1975, 3:184-186.
175. Kombogiorgas D., St George E.J., Chapman S., English M., Solanki G.A. Infantile clivus chordoma without clivus involvement: case report and review of the literature. Childs Nerv. Syst. 2006, 22:1369-1374.
176. Lountzis N.I., Hogarty M.D., Kim H.J., Junkins-Hopkins J.M. Cutaneous metastatic chordoma with concomitant tuberous sclerosis. J. Am. Acad. Dermatol. 2006, 55:S6-S10.
177. Schroeder B.A., Wells R.G., Starshak R.J., Sty J.R. Clivus chordoma in a child with tuberous sclerosis: CT and MR demonstration. J. Comput. Assist. Tomogr. 1987, 11:195-196.
178. Storm P.B., Magge S.N., Kazahaya K., Sutton L.N. Cervical chordoma in a patient with tuberous sclerosis presenting with shoulder pain. Pediatr. Neurosurg. 2007, 43:167-169.
179. Mirra J.M., Brien E.W. Giant notochordal hamartoma of intraosseous origin: a newly reported benign entity to be distinguished from chordoma. Skelet. Radiol. 2001, 30:698-709.
180. McMaster M.L., Goldstein A.M., Parry D.M. Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population. Journal of Medical Genetics 2011, 48(7):444-449.
181. Barry J.J., et al. The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients. Neurosurgery 2011, 231-240. (discussion 240-241).
182. Stacchiotti S., et al. Phase II study of imatinib in advanced chordoma. J. Clin. Oncol. 2012, 30:914-920.
183. Stacchiotti S., et al. Response to imatinib plus sirolimus in advanced chordoma. Ann. Oncol. 2009, 20:1886-1894.
184. Singhal N., Kotasek D., Parnis F.X. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 2009, 20:953-955.
185. Aplin A.E., Howe A., Alahari S.K., Juliano R.L. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 1998, 50:197-264.
186. Lien W.H., Klezovitch O., Vasioukhin V. Cadherin-catenin proteins in vertebrate development. Curr. Opin. Cell Biol. 2006, 18:499-506.
187. Shapiro L., Weis W.I. Structure and biochemistry of cadherins and catenins. Cold Spring Harbor Perspect. Biol. 2009, 1.
188. Alberts B. Cell junctions, cell adhesion, and the extracellular matric. Molecular Biology of the Cell 2008, 1131-1204. Garland Science, New York.
189. Kemler R. Classical cadherins. Semin. Cell Biol. 1992, 3:149-155.
190. Berx G., van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect. Biol. 2009, 1:a003129.
191. Wheelock M.J., Shintani Y., Maeda M., Fukumoto Y., Johnson K.R. Cadherin switching. J. Cell Sci. 2008, 121:727-735.
192. Hazan R.B., Qiao R., Keren R., Badano I., Suyama K. Cadherin switch in tumor progression. Ann. N. Y. Acad. Sci. 2004, 1014:155-163.
193. Jiang W.G. E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br. J. Surg. 1996, 83:437-446.
194. Mori K., Chano T., Kushima R., Hukuda S., Okabe H. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity. Virchows Arch. 2002, 440:123-127.
195. Naka T., et al. Immunohistochemical analysis of E-cadherin, α-catenin, β-catenin, γ-catenin, and neural cell adhesion molecule (NCAM) in chordoma. J. Clin. Pathol. 2001, 54:945-950.
196. Laskin W.B., Miettinen M. Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues. Arch. Pathol. Lab. Med. 2002, 126:425-431.
197. Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression [quest]. Oncogene 2008, 27:6920-6929.
198. Qian X., Karpova T., Sheppard A.M., McNally J., Lowy D.R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004, 23:1739-1748.
199. Lee K.H., et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur. Surg. Res. 2007, 39:208-215.
200. Aricescu A.R., Jones E.Y. Immunoglobulin superfamily cell adhesion molecules: zippers and signals. Curr. Opin. Cell Biol. 2007, 19:543-550.
201. Christensen C., Lauridsen J.B., Berezin V., Bock E., Kiselyov V.V. The neural cell adhesion molecule binds to fibroblast growth factor receptor 2. FEBS Lett. 2006, 580:3386-3390.
202. Kiselyov V.V. NCAM and the FGF-receptor. Structure and Function of the Neural Cell Adhesion Molecule NCAM 2010, 663:67-79. Springer, New York. V. Berezin (Ed.).
203. Jacobsen J., Kiselyov V., Bock E., Berezin V. A peptide motif from the second fibronectin module of the neural cell adhesion molecule, NCAM, NLIKQDDGGSPIRHY, is a binding site for the FGF receptor. Neurochem. Res. 2008, 33:2532-2539.
204. Hübschmann M., Skladchikova G. The role of ATP in the regulation of NCAM function. Neurochem. Res. 2008, 1-1.
205. Francavilla C., et al. The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. J. Cell Biol. 2009, 187:1101-1116.
206. Povlsen G.K. The neural cell adhesion molecule and epidermal growth factor receptor: signaling crosstalk. Structure and Function of the Neural Cell Adhesion Molecule NCAM 2010, 663:199-209. Springer, New York. V. Berezin (Ed.).
207. Schwab J.H., et al. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol. Immunother. 2009, 58:339-349.
208. Pamir M.N., Ozduman K. Tumor-biology and current treatment of skull-base chordomas. Adv. Tech. Stand. Neurosurg. 2008, 33:35-129.
209. Cho N.H., et al. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur. Urol. 2003, 44:560-566.
210. Guo C.B., et al. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol. Diagn. Ther. 2007, 11:183-192.
211. Li H.C., et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res. Treat. 2004, 88:75-85.
212. Liu Z., et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 2010, 10:270.
213. Mohammad M.A., Ismael N.R., Shaarawy S.M., El-Merzabani M.M. Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer. Int. J. Biol. Markers 2010, 25:69-74.
214. Nart D., et al. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2010, 16:621-630.
215. Yang Q., et al. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat. Rec. 2010, 293:2012-2019.
216. Zhou C.X., Gao Y., Johnson N.W., Gao J. Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust. Dent. J. 2010, 55:385-389.
217. Naka T., et al. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am. J. Clin. Pathol. 2004, 122:926-930.
218. Naka T., et al. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum. Pathol. 2008, 39:217-223.
219. Rahmah N.N., Sakai K., Nakayama J., Hongo K. Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg. Rev. 2010, 33:167-173. (discussion 173).
220. Chen K.W., et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J. Neuro. Oncol. 2011, 101:357-363.
221. Froehlich E.V., et al. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis. Spine 2012, 37:E757-E767. (Phila Pa 1976).
222. Haeckel C., et al. Expression of cathepsin K in chordoma. Hum. Pathol. 2000, 31:834-840.
223. Naka T., et al. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology 2009, 54:607-613.
224. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
225. Longoni M., et al. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro. Oncol. 2008, 10:52-60.
226. Le L.P., et al. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One 2011, 6:e18846.
227. Duan Z., et al. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J. Orthop. Res. 2010, 28:746-752.
228. Burger H., et al. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005, 4:1270-1274.
229. Stacchiotti S., et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010, 17:211-219.
230. Grabellus F., et al. MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions. Tumour Biol 2010, 31:157-163.
231. Naka T., et al. Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer 2008, 112:104-110.
232. Park J.B., et al. Overexpressions of nerve growth factor and its tropomyosin-related kinase. A receptor on chordoma cells. Spine (Phila Pa 1976) 2007, 32:1969-1973.